Inhibikase Therapeutics Ownership | Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics Ownership Summary

Inhibikase Therapeutics is owned by 60.88% institutional investors, 12.99% insiders, and 26.13% retail investors. Sands capital ventures is the largest institutional shareholder, holding 12.23% of IKT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.00% of its assets in Inhibikase Therapeutics shares.

IKT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Inhibikase Therapeutics	60.88%	12.99%	26.13%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	306.59%	11.10%	-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Sands capital ventures	10.95M	12.23%	$21.35M
Soleus capital management	6.33M	7.06%	$12.33M
Fairmount funds management	6.13M	6.84%	$11.94M
Perceptive advisors	5.43M	6.07%	$10.59M
Adar1 capital management	5.12M	5.72%	$9.99M
Blackrock funding, inc. /de	2.73M	3.05%	$5.32M
Blackstone	2.64M	2.95%	$5.14M
Nantahala capital management	2.19M	2.45%	$4.27M
Stonepine capital management	733.79K	0.82%	$1.43M
Intech investment management	31.41K	0.04%	$61.24K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sands capital ventures	10.95M	4.20%	$21.35M
Fairmount funds management	6.13M	1.55%	$11.94M
Adar1 capital management	5.12M	1.53%	$9.99M
Stonepine capital management	733.79K	1.40%	$1.43M
Soleus capital management	6.33M	0.82%	$12.33M
Perceptive advisors	5.43M	0.39%	$10.59M
Caxton	16.39K	0.32%	$31.97K
Nantahala capital management	2.19M	0.17%	$4.27M
Blackstone	2.64M	0.02%	$5.14M
Intech investment management	31.41K	0.00%	$61.24K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock funding, inc. /de	2.73M	0.00%	2.30M
Blackstone	2.64M	0.02%	567.59K
Intech investment management	31.41K	0.00%	31.41K
Sterling capital management	1.50K	-	1.50K
Raymond james financial	1.00K	-	1.00K

Top Sellers

Holder	Shares	% Assets	Change
Perceptive advisors	5.43M	0.39%	-492.71K
Stonepine capital management	733.79K	1.40%	-181.18K
Marshall wace, llp	-	-	-155.27K
Jane street group	-	-	-116.25K
Balyasny asset management	-	-	-81.16K

New Positions

Holder	Shares	% Assets	Change	Value
Intech investment management	31.41K	0.00%	31.41K	$61.24K
Sterling capital management	1.50K	-	1.50K	$2.94K
Raymond james financial	1.00K	-	1.00K	$1.95K

Sold Out

Holder	Change
Point72 (difc)	-1.98K
Cubist systematic strategies	-9.04K
Brevan howard capital management lp	-10.38K
Capstone investment advisors	-11.07K
Prelude capital management	-11.10K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	48	6.67%	54,512,380	20.28%	60	2.38%	37	19.35%	6	100.00%
Mar 31, 2025	47	51.61%	51,462,756	2.80%	57	0.13%	31	3.33%	3	-
Dec 31, 2024	31	181.82%	50,059,308	5719.28%	211	1604.08%	30	500.00%	-	-100.00%
Sep 30, 2024	11	-8.33%	860,232	2.84%	3	29.15%	5	-28.57%	2	-
Jun 30, 2024	12	-	836,496	306.94%	3	469.42%	7	40.00%	2	-50.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	2.23M	3.00%	-49.11K
iShares Russell 2000 ETF	808.55K	1.09%	-15.33K
iShares Russell 2000 Value ETF	476.56K	0.64%	354.00
Vanguard Institutional Extnd Mkt Idx Tr	343.15K	0.46%	-140.20K
Vanguard Russell 2000 ETF	290.81K	0.39%	-16.97K
State St Russell Sm Cap® Indx SL Cl I	211.70K	0.28%	-
Schwab Small Cap Index	152.30K	0.20%	-
Fidelity Extended Market Index	151.18K	0.20%	-395.00
NT R2000 Index Fund - NL	146.24K	0.20%	146.24K
Fidelity Select Biotechnology	144.17K	0.19%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 21, 2024	Bellini Roberto	-	Buy	$2.00M
Oct 21, 2024	Kush Arvind	-	Buy	$198.65K
Oct 21, 2024	Munshi Amit	-	Buy	$500.05K
Aug 16, 2022	Werner Milton H.	President and CEO	Buy	$4.00K
May 27, 2022	Werner Milton H.	President and CEO	Buy	$4.88K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	3	-
2024 Q3	-	-
2024 Q2	-	-

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics shareholders are primarily institutional investors at 60.88%, followed by 12.99% insiders and 26.13% retail investors. The average institutional ownership in Inhibikase Therapeutics's industry, Biotech Stocks , is 306.59%, which Inhibikase Therapeutics falls below.

Who owns the most shares of Inhibikase Therapeutics?

Inhibikase Therapeutics’s largest shareholders are Sands capital ventures (10.95M shares, 12.23%), Soleus capital management (6.32M shares, 7.06%), and Fairmount funds management (6.12M shares, 6.84%). Together, they hold 26.13% of Inhibikase Therapeutics’s total shares outstanding.

Does Blackrock own Inhibikase Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Inhibikase Therapeutics.

Who is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested?

Sands capital ventures is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.20% of its assets in 10.95M Inhibikase Therapeutics shares, valued at 21.35M$.

Who is the top mutual fund holder of Inhibikase Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Inhibikase Therapeutics shares, with 3.00% of its total shares outstanding invested in 2.23M Inhibikase Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools